ACURA PHARMACEUTICALS, INC 8-K

What Happened
Acura Pharmaceuticals filed an 8-K on May 7, 2026 saying it received four short-term loans of $100,000 each from Abuse Deterrent Pharma, LLC on March 30, April 3, April 20 and May 5, 2026. Combined with prior borrowings and the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, the company reports a principal balance of $10,294,279 and accrued interest of approximately $1,090,000 as of May 5, 2026. The Note carries a 5.25% interest rate; overdue amounts bear 7.5% interest after non-payment.

Key Details

• Four new loans of $100,000 each dated Mar 30, Apr 3, Apr 20 and May 5, 2026 from Abuse Deterrent Pharma, LLC.
• Total secured promissory note principal: $10,294,279; accrued interest ≈ $1,090,000 (as of May 5, 2026).
• Interest rate: 5.25% annual; default/non‑payment interest rate: 7.5% per annum. Events of default include bankruptcy, failure to pay that continues 5 days, or admitting inability to pay debts.
• Company states funds will be used for day‑to‑day operations and warns that without additional financing by the end of May 2026 it may need to scale back or cease operations, potentially leading to furloughs, layoffs or bankruptcy.

Why It Matters
This filing shows Acura is relying on related-party loans to cover near-term operating needs and faces a sizable secured debt load with material accrued interest. The company explicitly warns that failure to obtain additional financing by the end of May 2026 could force operational cutbacks or bankruptcy, a development that would be highly material to shareholders. Investors should watch for further financing announcements, debt renegotiation, or operational changes.